Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation

Corporate Breaking News

Home : Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation

Dec 08 2022	Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation
Idefirix® is granted full access and reimbursement in line with the indication approved by the European Medicines Agency (EMA).1 The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix® to enable kidney...


Source:https://www.prnewswire.com:443/news-releases/hansa-biopharma-announces-positive-reimbursement-decision-in-italy-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-patients-in-kidney-transplantation-301697960.html

Related News
» NFTs et Métavers de La Demeure du Chaos, Musée d'art contemporain et siège social d'Artprice by Artmarket.com, sont une réalité selon le n°2208 du magazine mensuel Géomètre (création 1847) » PRODATA Partners with Malwarebytes to Effectively Combat Regional Cyberthreats with Malwarebytes' Next-Generation Cybersecurity Platform